

Joshua Craig and Mahesh Karwa Honored with Luitpold President's Award

Columbus, OH (August 23, 2013) - Luitpold Pharmaceuticals, Inc. and PharmaForce, Inc. are proud to present the distinguished Luitpold President's Award to two recipients, Joshua Craig and Mahesh Karwa. The President's award, which recognizes outstanding contributions to Luitpold Pharmaceuticals, has been awarded to these individuals for their exemplary work towards the Injectafer FDA approval. In recognition of their significant involvement and diligence during Injectafer's development, a ceremony was held on Friday August 23, 2013 to honor Karwa and Craig and present them with their esteemed awards.



From left to right: Gopal Anyarambhatla, Mahesh Karwa, Dante Serricchio, Joshua Craig



“Seamless collaboration with our parent company, Luitpold Pharmaceuticals, and timely support from Vifor Pharma enabled the PharmaForce team to meet tight timelines and earn FDA approval for Injectafer,” said Vice President of Research and Development, Gopal Anyarambhatla, of their accomplishments.

Joshua Craig, PharmaForce, Inc. Regulatory Affairs Associate, is largely responsible for assembling the NDA submission for Injectafer. He coordinated the regulatory filing activities between Luitpold and PharmaForce followed by a seamless submission containing zero deficiencies. This October will mark Joshua's tenth year with PharmaForce.

Mahesh Karwa, R&D Sr. Analytical Development Scientist, has been a valuable member of PharmaForce since 2010. Mahesh played a critical role in validation transfer of analytical methodologies, in-process release stability testing of registration batches, and the technology transfer during the course of Injectafer's development process.

